MDMA Annual Report Submitted to FDA

On January 15, 2013, MAPS submitted our MDMA Annual Report to the U.S. Food and Drug Administration. Annual reports give the FDA an overview of completed, ongoing, and planned studies for specific Investigational New Drug (IND) Applications. This report covers the period from October 2, 2011 through October 1, 2012, and provides a cumulative listing of all studies using MDMA under our U.S. IND #63,384, including a comprehensive analysis of MDMA’s risk/benefit profile when used in psychotherapy for PTSD.